此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

裸盖菇素辅助认知加工疗法治疗慢性创伤后应激障碍

2026年10月1日 更新者:Unity Health Toronto

裸盖菇素辅助集体认知处理疗法治疗慢性创伤后应激障碍:一项开放标签试验

This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

研究概览

详细说明

Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.

Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.

研究类型

介入性

注册 (估计的)

15

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5S 1A1
        • St. Michael's Hospital, Unity Health Toronto

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
  2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
  3. Are willing to refrain from taking any psychiatric medications during the study period.

Exclusion Criteria:

  1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;
  2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
  3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
  4. Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
  5. History of seizure disorder;
  6. Uncontrolled insulin-dependent diabetes;
  7. Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF);
  8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;
  9. Lifetime history of substance-induced psychosis;
  10. Lifetime history of substance use disorder with a hallucinogen;
  11. History of alcohol use disorder in the past 3 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental

Single dose of psilocybin 25mg + Massed cognitive processing therapy

Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility and tolerability
大体时间:Up to 16 weeks

Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events.

Up to 16 weeks

次要结果测量

结果测量
措施说明
大体时间
儿童创伤问卷简版(CTQ-SF)
大体时间:筛选
筛选
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
大体时间:Up to 16 weeks

The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms.

Up to 16 weeks
Posttraumatic stress disorder Checklist-5 (PCL-5)
大体时间:Up to 16 weeks

The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD.

Up to 16 weeks
Patient Health Questionnaire-9 (PHQ-9)
大体时间:Up to 16 weeks

The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).

Up to 16 weeks
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
大体时间:Up to 16 weeks

Total score ranges from 0 to 21; a higher score denotes greater symptom severity.

Up to 16 weeks
Dissociative Experiences Scale II (DES-II)
大体时间:Up to 13 weeks

The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences.

Up to 13 weeks
Pittsburgh Sleep Quality Index (PSQI)
大体时间:Up to 13 weeks

The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.

Up to 13 weeks
World Health Organization Well-Being Index, 5-item (WHO-5)
大体时间:Up to 16 weeks

The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.

Up to 16 weeks
Quality of relationships inventory (QRI)
大体时间:Up to 13 weeks

The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true.

Up to 13 weeks
Inventory of psychosocial functioning (IPF)
大体时间:Up to 13 weeks

The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days.

Up to 13 weeks
Posttraumatic Maladaptive Beliefs Scale (PMBS)
大体时间:Up to 13 weeks

The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure.

Up to 13 weeks
Brief Experiential Avoidance Questionnaire (BEAQ)
大体时间:Up to 13 weeks

The BEAQ is a 15-item self-report measure of experiential avoidance.

Up to 13 weeks
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
大体时间:Up to 13 weeks

The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility.

Up to 13 weeks
Working Alliance Inventory- Short Form (WAI-SF)
大体时间:Up to Day 7

The WAI-SF is a patient-rated measure of the alliance between a therapist and client.

Up to Day 7
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
大体时间:Up to 13 weeks

The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults.

Up to 13 weeks
Self-Compassion Scale-Short Form (SCS-SF)
大体时间:Up to 13 weeks

The SCS-SF is a 12-item self-report measure of self-compassion.

Up to 13 weeks
Psychological Insight Questionnaire (PIQ)
大体时间:Up to Day 3

The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic.

Up to Day 3
Emotional Breakthrough Inventory (EBI)
大体时间:Up to Day 3

The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state.

Up to Day 3
Altered States of Consciousness Rating Scale (ASC)
大体时间:Up to Day 3

The ASC measures altered states of consciousness.

Up to Day 3
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
大体时间:Up to Day 3

The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.

Up to Day 3

其他结果措施

结果测量
措施说明
大体时间
Effect on digital physiological passive data collected through the use of a wearable device
大体时间:Up to 16 weeks

Example: sleep, activity

Up to 16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月1日

初级完成 (估计的)

2028年1月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2024年4月18日

首先提交符合 QC 标准的

2024年4月22日

首次发布 (实际的)

2024年4月26日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2025年12月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅